Ivabradine for treating chronic heart failure

SHIFT. But it considered that the recommendation for ivabradine was not based on sex or age, does not vary according to the sex or age of the patient, and that all patients would benefit from ivabradine. The committee considered that these were not equality issues under the legislation. The committee therefore concluded that its recommendations do not have a particular impact on any of the groups whose interests are protected by the legislation and that there is no need to alter or add to its recommendations. 4.21 Overall the committee considered the effectiveness of ivabradine in the subgroup of patients with a resting heart rate of 75 bpm or more derived from SHIFT, the generalisability of the trial to UK clinical practice, the adverse event profile of ivabradine, the position of ivabradine in the treatment pathway of chronic heart failure (that is after optimisation on standard care therapy with ACE inhibitors, beta-blockers and aldosterone antagonists) and the way ivabradine will be prescribed in clinical practice. It also considered the robustness of the economic model, the realistic nature of the assumptions used in the model, the plausibility of the base-case ICERs and the range of sensitivity analyses presented by the manufacturer.
